Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m dianexin

Drug Profile

Tc 99m dianexin

Alternative Names: 99m-Tc-HYNIC annexin V; 99m-Tc-HYNIC dianexin; 99m-Tc-HYNIC-annexin A5; 99mTc-4,5-bis(thioacetamido)pentanoyl-annexin-V; 99mTc-BTAP-annexin-V; Apomate; Tc 99m annexin-V; Tc 99m-HYNIC annexin V; Technetium Tc 99m BTAP-annexin-V; Technetium Tc 99m HYNIC annexin V

Latest Information Update: 31 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Class Calcium binding proteins; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tissue degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Tissue degeneration

Most Recent Events

  • 07 Nov 2006 AnorMED has been acquired by Genzyme Corporation
  • 06 Jul 2004 North American Sicentific presented observations from an ongoing European clinical trial with Tc 99m dianexin in patients with non-small lung cancer
  • 14 Oct 2003 North American Scientific announced preliminary data from an ongoing European study with Tc 99m dianexin
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top